Cargando…
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747699/ https://www.ncbi.nlm.nih.gov/pubmed/36529030 http://dx.doi.org/10.1016/j.cyto.2022.156111 |
_version_ | 1784849662396596224 |
---|---|
author | Samaras, Charilaos Kyriazopoulou, Evdoxia Poulakou, Garyfallia Reiner, Eran Kosmidou, Maria Karanika, Ioanna Petrakis, Vasileios Adamis, George Gatselis, Nikolaos K. Fragkou, Archontoula Rapti, Aggeliki Taddei, Eleonora Kalomenidis, Ioannis Chrysos, George Bertoli, Giulia Kainis, Ilias Alexiou, Zoi Castelli, Francesco Saverio Serino, Francesco Bakakos, Petros Nicastri, Emanuele Tzavara, Vassiliki Kostis, Evangelos Dagna, Lorenzo Koukidou, Sofia Tzatzagou, Glykeria Chini, Maria Bassetti, Matteo Trakatelli, Christina Tsoukalas, George Selmi, Carlo Samarkos, Michael Pyrpasopoulou, Athina Masgala, Aikaterini Antonakis, Emmanouil Argyraki, Aikaterini Akinosoglou, Karolina Sympardi, Styliani Panagopoulos, Periklis Milionis, Haralampos Metallidis, Simeon Syrigos, Konstantinos N. Angel, Alon Dalekos, George N. Netea, Mihai G. Giamarellos-Bourboulis, Evangelos J. |
author_facet | Samaras, Charilaos Kyriazopoulou, Evdoxia Poulakou, Garyfallia Reiner, Eran Kosmidou, Maria Karanika, Ioanna Petrakis, Vasileios Adamis, George Gatselis, Nikolaos K. Fragkou, Archontoula Rapti, Aggeliki Taddei, Eleonora Kalomenidis, Ioannis Chrysos, George Bertoli, Giulia Kainis, Ilias Alexiou, Zoi Castelli, Francesco Saverio Serino, Francesco Bakakos, Petros Nicastri, Emanuele Tzavara, Vassiliki Kostis, Evangelos Dagna, Lorenzo Koukidou, Sofia Tzatzagou, Glykeria Chini, Maria Bassetti, Matteo Trakatelli, Christina Tsoukalas, George Selmi, Carlo Samarkos, Michael Pyrpasopoulou, Athina Masgala, Aikaterini Antonakis, Emmanouil Argyraki, Aikaterini Akinosoglou, Karolina Sympardi, Styliani Panagopoulos, Periklis Milionis, Haralampos Metallidis, Simeon Syrigos, Konstantinos N. Angel, Alon Dalekos, George N. Netea, Mihai G. Giamarellos-Bourboulis, Evangelos J. |
author_sort | Samaras, Charilaos |
collection | PubMed |
description | OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-care setting, alternative biomarkers are needed. We investigated the performance of C-reactive protein (CRP), interferon gamma-induced protein-10 (IP-10) and TNF-related apoptosis-inducing ligand (TRAIL) for predicting SRF or death in COVID-19. METHODS: Two cohorts were studied; one discovery cohort with 534 patients from the SAVE-MORE clinical trial; and one validation cohort with 364 patients from the SAVE trial including also 145 comparators. CRP, IP-10 and TRAIL were measured by the MeMed Key® platform in order to select the biomarker with the best prognostic performance for the early prediction of progression into SRF or death. RESULTS: IP-10 had the best prognostic performance: baseline concentrations 2000 pg/ml or higher predicted equally well to suPAR (sensitivity 85.0 %; negative predictive value 96.6 %). Odds ratio for poor outcome among anakinra-treated participants of the SAVE-MORE trial was 0.35 compared to placebo when IP-10 was 2,000 pg/ml or more. IP-10 could divide different strata of severity for SRF/death by day 14 in the validation cohort. Anakinra treatment decreased this risk irrespective the IP-10 concentrations. CONCLUSIONS: IP-10 concentrations of 2,000 pg/ml or higher are a valid alternative to suPAR for the early prediction of progression into SRF or death the first 14 days from hospital admission for COVID-19 and they may guide anakinra treatment. Trial registration. ClinicalTrials.gov, NCT04680949 and NCT04357366. |
format | Online Article Text |
id | pubmed-9747699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97476992022-12-14 Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia Samaras, Charilaos Kyriazopoulou, Evdoxia Poulakou, Garyfallia Reiner, Eran Kosmidou, Maria Karanika, Ioanna Petrakis, Vasileios Adamis, George Gatselis, Nikolaos K. Fragkou, Archontoula Rapti, Aggeliki Taddei, Eleonora Kalomenidis, Ioannis Chrysos, George Bertoli, Giulia Kainis, Ilias Alexiou, Zoi Castelli, Francesco Saverio Serino, Francesco Bakakos, Petros Nicastri, Emanuele Tzavara, Vassiliki Kostis, Evangelos Dagna, Lorenzo Koukidou, Sofia Tzatzagou, Glykeria Chini, Maria Bassetti, Matteo Trakatelli, Christina Tsoukalas, George Selmi, Carlo Samarkos, Michael Pyrpasopoulou, Athina Masgala, Aikaterini Antonakis, Emmanouil Argyraki, Aikaterini Akinosoglou, Karolina Sympardi, Styliani Panagopoulos, Periklis Milionis, Haralampos Metallidis, Simeon Syrigos, Konstantinos N. Angel, Alon Dalekos, George N. Netea, Mihai G. Giamarellos-Bourboulis, Evangelos J. Cytokine Article OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-care setting, alternative biomarkers are needed. We investigated the performance of C-reactive protein (CRP), interferon gamma-induced protein-10 (IP-10) and TNF-related apoptosis-inducing ligand (TRAIL) for predicting SRF or death in COVID-19. METHODS: Two cohorts were studied; one discovery cohort with 534 patients from the SAVE-MORE clinical trial; and one validation cohort with 364 patients from the SAVE trial including also 145 comparators. CRP, IP-10 and TRAIL were measured by the MeMed Key® platform in order to select the biomarker with the best prognostic performance for the early prediction of progression into SRF or death. RESULTS: IP-10 had the best prognostic performance: baseline concentrations 2000 pg/ml or higher predicted equally well to suPAR (sensitivity 85.0 %; negative predictive value 96.6 %). Odds ratio for poor outcome among anakinra-treated participants of the SAVE-MORE trial was 0.35 compared to placebo when IP-10 was 2,000 pg/ml or more. IP-10 could divide different strata of severity for SRF/death by day 14 in the validation cohort. Anakinra treatment decreased this risk irrespective the IP-10 concentrations. CONCLUSIONS: IP-10 concentrations of 2,000 pg/ml or higher are a valid alternative to suPAR for the early prediction of progression into SRF or death the first 14 days from hospital admission for COVID-19 and they may guide anakinra treatment. Trial registration. ClinicalTrials.gov, NCT04680949 and NCT04357366. The Author(s). Published by Elsevier Ltd. 2023-02 2022-12-14 /pmc/articles/PMC9747699/ /pubmed/36529030 http://dx.doi.org/10.1016/j.cyto.2022.156111 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Samaras, Charilaos Kyriazopoulou, Evdoxia Poulakou, Garyfallia Reiner, Eran Kosmidou, Maria Karanika, Ioanna Petrakis, Vasileios Adamis, George Gatselis, Nikolaos K. Fragkou, Archontoula Rapti, Aggeliki Taddei, Eleonora Kalomenidis, Ioannis Chrysos, George Bertoli, Giulia Kainis, Ilias Alexiou, Zoi Castelli, Francesco Saverio Serino, Francesco Bakakos, Petros Nicastri, Emanuele Tzavara, Vassiliki Kostis, Evangelos Dagna, Lorenzo Koukidou, Sofia Tzatzagou, Glykeria Chini, Maria Bassetti, Matteo Trakatelli, Christina Tsoukalas, George Selmi, Carlo Samarkos, Michael Pyrpasopoulou, Athina Masgala, Aikaterini Antonakis, Emmanouil Argyraki, Aikaterini Akinosoglou, Karolina Sympardi, Styliani Panagopoulos, Periklis Milionis, Haralampos Metallidis, Simeon Syrigos, Konstantinos N. Angel, Alon Dalekos, George N. Netea, Mihai G. Giamarellos-Bourboulis, Evangelos J. Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia |
title | Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia |
title_full | Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia |
title_fullStr | Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia |
title_full_unstemmed | Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia |
title_short | Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia |
title_sort | interferon gamma-induced protein 10 (ip-10) for the early prognosis of the risk for severe respiratory failure and death in covid-19 pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747699/ https://www.ncbi.nlm.nih.gov/pubmed/36529030 http://dx.doi.org/10.1016/j.cyto.2022.156111 |
work_keys_str_mv | AT samarascharilaos interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT kyriazopoulouevdoxia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT poulakougaryfallia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT reinereran interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT kosmidoumaria interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT karanikaioanna interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT petrakisvasileios interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT adamisgeorge interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT gatselisnikolaosk interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT fragkouarchontoula interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT raptiaggeliki interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT taddeieleonora interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT kalomenidisioannis interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT chrysosgeorge interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT bertoligiulia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT kainisilias interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT alexiouzoi interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT castellifrancesco interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT saverioserinofrancesco interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT bakakospetros interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT nicastriemanuele interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT tzavaravassiliki interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT kostisevangelos interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT dagnalorenzo interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT koukidousofia interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT tzatzagouglykeria interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT chinimaria interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT bassettimatteo interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT trakatellichristina interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT tsoukalasgeorge interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT selmicarlo interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT samarkosmichael interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT pyrpasopoulouathina interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT masgalaaikaterini interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT antonakisemmanouil interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT argyrakiaikaterini interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT akinosogloukarolina interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT sympardistyliani interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT panagopoulosperiklis interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT milionisharalampos interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT metallidissimeon interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT syrigoskonstantinosn interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT angelalon interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT dalekosgeorgen interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT neteamihaig interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia AT giamarellosbourboulisevangelosj interferongammainducedprotein10ip10fortheearlyprognosisoftheriskforsevererespiratoryfailureanddeathincovid19pneumonia |